EWOLUTION Registry Outcomes & Clinical Impact

EWOLUTION, the largest prospective real‐life registry studying the WATCHMAN LAAC device in more than 1000 patients. WATCHMAN LAAC is a device designed to reduce the risk of stroke in patients with Atrial Fibrillation by preventing thrombus embolization from the left atrial appendage.

Spotlight

Daiichi Sankyo, Inc.

Daiichi Sankyo, Inc. headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Daiichi Sankyo, Co., Ltd. and a member of the Daiichi Sankyo Group. Global clinical development and regulatory activities are headquartered at Daiichi Sankyo Pharma Development in Edison, New Jersey.

OTHER VIDEOS

Centralizing your organization's healthcare data

video | September 11, 2023

Your healthcare organization needs a centralized, trustworthy data asset. Top health systems and health plans partner with Arcadia to drive ROI, improve workflows, and operationalize insights across their growing Medicare Advantage, MSSP, and commercial populations....

Watch Now

Accelerate Breakthroughs in Health Care and Life Sciences with SAS

video | September 6, 2023

The answers to the world’s toughest health care challenges are in the data. SAS helps customers bring together a complex ecosystem of health care and life sciences data, accelerate insights and improve lives. Let’s find your next breakthrough....

Watch Now

FASTlab HPLC+

video | September 7, 2023

Learn more about the new FASTlab HPLC+. Efficient HPLC purification and reformulation in one. Increased flexibility and efficiency of R&D tracer production enabling nearly all compounds and synthesis methods. Integrated reformulation system enabling higher dilution volume and faster mixing to empower your clinical research....

Watch Now

Digital Healthcare for Remote Communities

video | September 8, 2023

The University of Galway is bringing 5G connectivity to Clare Island in Ireland, improving digital inclusion and access to quality care....

Watch Now

Spotlight

Daiichi Sankyo, Inc.

Daiichi Sankyo, Inc. headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Daiichi Sankyo, Co., Ltd. and a member of the Daiichi Sankyo Group. Global clinical development and regulatory activities are headquartered at Daiichi Sankyo Pharma Development in Edison, New Jersey.

Events